Date: 2011-05-10
Type of information: Fundraising
Company: Stermergie Biotechnology (Switzerland)
Investors: private investors
Amount: CHF 1.8 million (€1.3 million)
Funding type:
Planned used: This Seed Financing will finance the selection of the lead compound, the in vivo validation of compounds against brain cancer-initiating cells, the further development of companion diagnostics as well as the ongoing translation of Stemergie\'s cancer-initiating cells technology in a second indication.
Others: Stemergie has realized the first closing of CHF 1.8 million through private investors.
Therapeutic area: Cancer - Oncology
